Vaccines for allergy

Current Opinion in Immunology

Volumn 24, Issue 3, 2012, Pages 354-360

  Linhart, Birgit ^a   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; POLLEN ANTIGEN; RECOMBINANT ALLERGEN; VACCINE;

ALLERGY; ALLERGY TEST; CYTOKINE PRODUCTION; FOOD ALLERGY; HOUSE DUST ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MAST CELL DEGRANULATION; NONHUMAN; ORAL IMMUNOTHERAPY; POLLEN ALLERGY; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; VACCINES;

EID: 84862683004     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.03.006     Document Type: Review

References (75)

1. Flöistrup H., Swartz J., Bergström A., Alm J.S., Scheynius A., van Hage M., Waser M., Braun-Fahrländer C., Schram-Bijkerk D., Huber M., et al. Allergic disease and sensitization in Steiner school children. J Allergy Clin Immunol 2006, 117:59-66.
2. Larché M., Akdis C.A., Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761-771.
3. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 1:1572-1573.
4. Dunbar W.P. Zur Ursache und spezifischen Heilung des Heufiebers. Dtsch Med Wochenschr 1903, 9:24-28.
5. Cooke R.A., Barnard J.H., Hebald S., Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy. J Exp Med 1935, 62:733-750.
6. Brunetto B., Tinghino R., Braschi M.C., Antonicelli L., Pini C., Iacovacci P. Characterization and comparison of commercially available mite extracts for in vivo diagnosis. Allergy 2010, 65:184-190.
7. Curin M., Reininger R., Swoboda I., Focke M., Valenta R., Spitzauer S. Skin prick test extracts for dog allergy diagnosis show considerable variations regarding the content of major and minor dog allergens. Int Arch Allergy Immunol 2011, 154:258-263.
8. Blank S., Seismann H., Michel Y., McIntyre M., Cifuentes L., Braren I., Grunwald T., Darsow U., Ring J., Bredehorst R., et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011, 66:1322-1329.
9. Focke M., Swoboda I., Marth K., Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010, 40:385-397.
10. Valenta R., Ferreira F., Focke-Tejkl M., Linhart B., Niederberger V., Swoboda I., Vrtala S. From allergen genes to allergy vaccines. Annu Rev Immunol 2010, 28:211-241.
11. Hiller R., Laffer S., Harwanegg C., Huber M., Schmidt W.M., Twardosz A., Barletta B., Becker W.M., Blaser K., Breiteneder H., et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002, 16:414-416.
12. Sastre J., Landivar M.E., Ruiz-García M., Andregnette-Rosigno M.V., Mahillo I. How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy 2012, 67:709-711.
13. Mittermann I., Zidarn M., Silar M., Markovic-Housley Z., Aberer W., Korosec P., Kosnik M., Valenta R. Recombinant allergen-based IgE testing to distinguish bee and wasp allergy. J Allergy Clin Immunol 2010, 125:1300-1307.
14. Arkestål K., Sibanda E., Thors C., Troye-Blomberg M., Mduluza T., Valenta R., Grönlund H., van Hage M. Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α1,3-galactose. J Allergy Clin Immunol 2011, 127:1024-1028.
15. Smith W., O'Neil S.E., Hales B.J., Chai T.L., Hazell L.A., Tanyaratsrisakul S., Piboonpocanum S., Thomas W.R. Two newly identified cat allergens: the von Ebner gland protein Fel d 7 and the latherin-like protein Fel d 8. Int Arch Allergy Immunol 2011, 156:159-170.
16. Hochwallner H., Schulmeister U., Swoboda I., Balic N., Geller B., Nystrand M., Härlin A., Thalhamer J., Scheiblhofer S., Niggemann B., et al. Microarray and allergenic activity assessment of milk allergens. Clin Exp Allergy 2010, 40:1809-1818.
17. Pastorello E.A., Farioli L., Pravettoni V., Scibilia J., Mascheri A., Borgonovo L., Piantanida M., Primavesi L., Stafylaraki C., Pasqualetti S., et al. Pru p 3-sensitised Italian peach-allergic patients are less likely to develop severe symptoms when also presenting IgE antibodies to Pru p 1 and Pru p 4. Int Arch Allergy Immunol 2011, 156:362-372.
18. Alessandri C., Zennaro D., Scala E., Ferrara R., Bernardi M.L., Santoro M., Palazzo P., Mari A. Ovomucoid (Gal d 1) specific IgE detected by microarray system predict tolerability to boiled hen's egg and an increased risk to progress to multiple environmental allergen sensitisation. Clin Exp Allergy 2012, 42:441-450.
19. Martorell A., De la Hoz B., Ibáñez M.D., Bone J., Terrados M.S., Michavila A., Plaza A.M., Alonso E., Garde J., Nevot S., et al. Oral desensitization as a useful treatment in 2-year-old children with cow's milk allergy. Clin Exp Allergy 2011, 41:1297-1304.
20. Vickery B.P., Pons L., Kulis M., Steele P., Jones S.M., Burks A.W. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol 2010, 105:444-450.
21. Varshney P., Jones S.M., Scurlock A.M., Perry T.T., Kemper A., Steele P., Hiegel A., Kamilaris J., Carlisle S., Yue X., et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011, 127:654-660.
22. Constantin C., Quirce S., Poorafshar M., Touraev A., Niggemann B., Mari A., Ebner C., Akerström H., Heberle-Bors E., Nystrand M., et al. Micro-arrayed wheat seed and grass pollen allergens for component-resolved diagnosis. Allergy 2009, 64:1030-1037.
23. Bublin M., Dennstedt S., Buchegger M., Antonietta Ciardiello M., Bernardi M.L., Tuppo L., Harwanegg C., Hafner C., Ebner C., et al. The performance of a component-based allergen microarray for the diagnosis of kiwifruit allergy. Clin Exp Allergy 2011, 41:129-136.
24. Gadermaier E., Staikuniene J., Scheiblhofer S., Thalhamer J., Kundi M., Westritschnig K., Swoboda I., Flicker S., Valenta R. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation. Allergy 2011, 66:1174-1182.
25. Gadermaier E., Flicker S., Aberer W., Egger C., Reider N., Focke M., Vrtala S., Kundi M., Valenta R. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Int Arch Allergy Immunol 2010, 151:17-27.
26. Wambre E., Bonvalet M., Bodo V.B., Maillère B., Leclert G., Moussu H., Von Hofe E., Louise A., Balazuc A.M., Ebo D., et al. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses. Clin Exp Allergy 2011, 41:192-203.
27. Wambre E., Delong J.H., James E.A., Lafond R.E., Robinson D., Kwok W.W. Differentiation stage determines pathologic and protective allergen-specific CD4(+) T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012, 129:544-551.
28. Allam J.P., Würtzen P.A., Reinartz M., Winter J., Vrtala S., Chen K.W., Valenta R., Wenghoefer M., Appel T., Gros E., et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010, 126:638-645.
29. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., Riis B., Grønager P.M., Durham S.R. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121:512-518.
30. Pauli G., Larsen T.H., Rak S., Horak F., Pastorello E., Valenta R., Purohit A., Arvidsson M., Kavina A., Schroeder J.W., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122:951-960.
31. Pree I., Shamji M.H., Kimber I., Valenta R., Durham S.R., Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010, 40:1346-1352.
32. James L.K., Shamji M.H., Walker S.M., Wilson D.R., Wachholz P.A., Francis J.N., Jacobson M.R., Kimber I., Till S.J., Durham S.R. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011, 127:509-516.
33. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., Reisinger J., Pelzmann M., Hayek B., Kronqvist M., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2):14677-14682.
34. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., Li H., Coffman R., Seyfert V., Eiden J.J., Broide D., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355:1445-1455.
35. Linhart B, Valenta R: Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2011 Nov 17, PMID: 22100888. [Epub ahead of print].
36. Senti G., Johansen P., Kündig T.M. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol 2011, 352:71-84.
37. Dioszeghy V., Mondoulet L., Dhelft V., Ligouis M., Puteaux E., Benhamou P.H., Dupont C. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011, 186:5629-5637.
38. Mondoulet L., Dioszeghy V., Vanoirbeek J.A., Nemery B., Dupont C., Benhamou P.H. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 2011, 154:299-309.
39. Senti G., von Moos S., Tay F., Graf N., Sonderegger T., Johansen P., Kündig T.M. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012, 129:128-135.
40. Worm M., Lee H.H., Kleine-Tebbe J., Hafner R.P., Laidler P., Healey D., Buhot C., Verhoef A., Maillère B., Kay A.B., et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011, 127:89-97.
41. Campbell J.D., Buckland K.F., McMillan S.J., Kearley J., Oldfield W.L., Stern L.J., Grönlund H., van Hage M., Reynolds C.J., Boyton R.J., et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009, 206:1535-1547.
42. Neunkirchner A., Leb-Reichl V.M., Schmetterer K.G., Mutschlechner S., Kueng H.J., Haiderer D., Schuch K., Wallner M., Jahn-Schmid B., Bohle B., et al. Human TCR transgenic Bet v 1-specific Th1 cells suppress the effector function of Bet v 1-specific Th2 cells. J Immunol 2011, 187:4077-4087.
43. Schmetterer K.G., Haiderer D., Leb-Reichl V.M., Neunkirchner A., Jahn-Schmid B., Küng H.J., Schuch K., Steinberger P., Bohle B., Pickl W.F. Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner. J Allergy Clin Immunol 2011, 127:238-245.
44. Oldfield W.L., Larché M., Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:47-53.
45. Norman P.S., Ohman J.L., Long A.A., Creticos P.S., Gefter M.A., et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996, 154:1623-1628.
46. Moldaver D., Larché M. Immunotherapy with peptides. Allergy 2011, 66:784-791.
47. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002, 2:446-453.
48. Valenta R., Linhart B., Swoboda I., Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011, 66:775-783.
49. Chen K.W., Fuchs G., Sonneck K., Gieras A., Swoboda I., Douladiris N., Linhart B., Jankovic M., Pavkov T., Keller W., et al. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol Immunol 2008, 45:2486-2498.
50. Campana R., Vrtala S., Maderegger B., Jertschin P., Stegfellner G., Swoboda I., Focke-Tejkl M., Blatt K., Gieras A., Zafred D., et al. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol 2010, 126:1024-1031.
51. Vrtala S., Fohr M., Campana R., Baumgartner C., Valent P., Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen Bet v 1, for allergy vaccination. Vaccine 2011, 29:2140-2148.
52. Grundström J., Neimert-Andersson T., Kemi C., Nilsson O.B., Saarne T., Andersson M., van Hage M., Gafvelin G. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol 2012, 157:136-146.
53. Saarne T., Neimert-Andersson T., Grönlund H., Jutel M., Gafvelin G., van Hage M. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011, 66:255-263.
54. Wallner M., Hauser M., Himly M., Zaborsky N., Mutschlechner S., Harrer A., Asam C., Pichler U., van Ree R., Briza P., et al. Reshaping the Bet v 1 fold modulates T(H) polarization. J Allergy Clin Immunol 2011, 127:1571-1578.
55. Chen KW, Blatt K, Thomas WR, Swoboda I, Valent P, Valenta R, Vrtala S: Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol 2012.
56. Nilsson O.B., Adedoyin J., Rhyner C., Neimert-Andersson T., Grundström J., Berndt K.D., Crameri R., Grönlund H. In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One 2011, 6:e24558.
57. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005, 116:608-613.
58. Gieras A., Cejka P., Blatt K., Focke-Tejkl M., Linhart B., Flicker S., Stoecklinger A., Marth K., Drescher A., Thalhamer J., et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 2011, 186:5333-5344.
59. Twaroch T.E., Focke M., Civaj V., Weber M., Balic N., Mari A., Ferrara R., Quirce S., Spitzauer S., Swoboda I., et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011, 128:178-184.
60. Twaroch TE, Focke M, Fleischmann K, Balic N, Meyerweck S, Lupinek C, Blatt K, Mari A, Ebner C, Valent P, et al.: Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy 2012.
61. Chen K.W., Focke-Tejkl M., Blatt K., Kneidinger M., Gieras A., Dall'antonia F., Faé I., Fischer G., Keller W., Valent P., et al. Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Exp Allergy Immunol 2012, 67:609-621.
62. Edlmayr J., Niespodziana K., Linhart B., Focke-Tejkl M., Westritschnig K., Scheiblhofer S., Stoecklinger A., Kneidinger M., Valent P., Campana R., et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009, 182:6298-6306.
63. Niespodziana K., Focke-Tejkl M., Linhart B., Civaj V., Blatt K., Valent P., van Hage M., Grönlund H., Valenta R. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011, 127:1562-1570.
64. Edlmayr J., Niespodziana K., Focke-Tejkl M., Linhart B., Valenta R. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases. Curr Top Microbiol Immunol 2011, 352:121-140.
65. Wallmann J., Epstein M.M., Singh P., Brunner R., Szalai K., El-Housseiny L., Pali-Schöll I., Jensen-Jarolim E. Mimotope vaccination for therapy of allergic asthma: anti-inflammatory effects in a mouse model. Clin Exp Allergy 2010, 40:650-658.
66. Flicker S., Gadermaier E., Madritsch C., Valenta R. Passive immunization with allergen-specific antibodies. Curr Top Microbiol Immunol 2011, 352:141-159.
67. Padavattan S., Flicker S., Schirmer T., Madritsch C., Randow S., Reese G., Vieths S., Lupinek C., Ebner C., Valenta R., et al. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol 2009, 182:2141-2151.
68. Hecker J., Diethers A., Etzold S., Seismann H., Michel Y., Plum M., Bredehorst R., Blank S., Braren I., Spillner E. Generation and epitope analysis of human monoclonal antibody isotypes with specificity for the Timothy grass major allergen Phl p 5a. Mol Immunol 2011, 48:1236-1244.
69. Ellertsen L.K., Nygaard U.C., Melkild I., Løvik M. Maternal allergen immunisation to prevent sensitisation in offspring: Th2-polarising adjuvants are more efficient than a Th1-polarising adjuvant in mice. BMC Immunol 2010, 11:8.
70. Nakata K., Kobayashi K., Ishikawa Y., Yamamoto M., Funada Y., Kotani Y., Blumberg R.S., Karasuyama H., Yoshida M., Nishimura Y. The transfer of maternal antigen-specific IgG regulates the development of allergic airway inflammation early in life in an FcRn-dependent manner. Biochem Biophys Res Commun 2010, 395:238-243.
71. Victor J.R., Muniz B.P., Fusaro A.E., de Brito C.A., Taniguchi E.F., Duarte A.J., Sato M.N. Maternal immunization with ovalbumin prevents neonatal allergy development and up-regulates inhibitory receptor Fc gamma RIIB expression on B cells. BMC Immunol 2010, 11:11.
72. Baranyi U., Linhart B., Pilat N., Gattringer M., Bagley J., Muehlbacher F., Iacomini J., Valenta R., Wekerle T. Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells. J Immunol 2008, 180:8168-8175.
73. Baranyi U., Gattringer M., Boehm A., Marth K., Focke-Tejkl M., Bohle B., Blatt K., Valent P., Valenta R., Wekerle T. Expression of a major plant allergen as membrane-anchored and secreted protein in human cells with preserved T cell and B cell epitopes. Int Arch Allergy Immunol 2011, 156:259-266.
74. Baranyi U., Gattringer M., Valenta R., Wekerle T. Cell-based therapy in allergy. Curr Top Microbiol Immunol 2011, 352:161-179.
75. Roesler E., Weiss R., Weinberger E.E., Fruehwirth A., Stoecklinger A., Mostböck S., Ferreira F., Thalhamer J., Scheiblhofer S. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009, 124:1070-1077.